WebIbrutinib-associated aspergillosis Retrospective French surveillance study identified 33 cases of aspergillosis in ibrutinib-treated patients with CLL CNS aspergillosis in 11/27 (40%), most cases within 3 months of starting therapy All patients had refractory/relapsed CLL and other predisposing risk factors WebPonatinib is a third-generation TKI which potently inhibits the BCR-ABL tyrosine kinase. Single-agent ponatinib has high activity in patients with Ph+ ALL but has dose …
Clinical Value of MRD in ALL. BLCTT
Web1 sep. 2024 · The combination of HyperCVAD and ponatinib in the frontline setting has been shown to be effective with an estimated three-year OS of 76%, which is better than … Web1 sep. 2024 · A recent update of 86 patients treated with hyper-CVAD and ponatinib was reported with a median follow-up of 43 months. The 3-month complete molecular … joe biden chatham university
Combination of hyper-CVAD with ponatinib as first-line therapy …
WebWith a median duration of exposure to ponatinib of 4 months, only 3 cardio-vascular events were recorded despite a high incidence of risk factors, and overall safety was … http://www.indyhematologyreview.com/wp-content/uploads/2024/Presentations_2024/19KantarjianHagopFacultyPresentationApproved.pdf Web30 sep. 2015 · All participants received 8 cycles of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD) alternating with high-dose … integrated micro-electronics inc singapore